🟢 Eli Lilly is trading 6.2% up today after Q2 earnings beat and FDA breakthrough designation

Eli Lilly is trading 6.2% up today at $33,380 following stronger-than-expected Q2 earnings, positive oncology news, and a broader market rally.

• The company reported Q2 2026 revenue of $23.0 billion, a 48% increase year-over-year, and adjusted earnings per share of $8.38, both beating analyst expectations.
• Demand for its GLP-1 drugs, Mounjaro and Zepbound, was a primary driver for the strong financial results and increased full-year guidance.
• The FDA granted Breakthrough Therapy designation to olomorasib, the company's treatment for KRAS G12C-mutant pancreatic cancer.
• The stock also received additional momentum from a broader market rally across major U.S., European, and Asian indices.